OncoMatch/Clinical Trials/NCT06067503
Biomarkers to Detect Endocrine Therapy Resistance
Is NCT06067503 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including 18F-fluorofuranylnorprogesterone and Liquid Biopsy for metastatic cancer.
Treatment: 18F-fluorofuranylnorprogesterone · Liquid Biopsy · Positron Emission Tomography/Computed Tomography — This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tumor cell (CTC) liquid biopsy will be correlated with clinical response to endocrine therapy and progression-free survival in the above cohort of patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (ER ≥1 percent by IHC)
ER/PR-positive (defined as ER ≥1 percent and PR ≥1 percent by IHC)
Required: PR (PGR) overexpression (PR ≥1 percent by IHC)
ER/PR-positive (defined as ER ≥1 percent and PR ≥1 percent by IHC)
Required: HER2 (ERBB2) wild-type (HER2-negative)
HER2-negative
Disease stage
Required: Stage IV
Metastatic disease required
advanced or metastatic LBC
Lab requirements
Blood counts
as indicated by standard laboratory tests (CBC) allowing for systemic breast cancer treatment per treating oncologist
Liver function
as indicated by standard laboratory tests (liver function tests or CMP) allowing for systemic breast cancer treatment per treating oncologist
Adequate organ function as indicated by standard laboratory tests (CBC, liver function tests or CMP) allowing for systemic breast cancer treatment per treating oncologist
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UW Carbone Cancer Center · Madison, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify